| Literature DB >> 34031465 |
Nick Wilson1,2, Michael G Baker3, Tony Blakely4, Martin Eichner5,6.
Abstract
We aimed to estimate the risk of COVID-19 outbreaks associated with air travel to a COVID-19-free country [New Zealand (NZ)]. A stochastic version of the SEIR model CovidSIM v1.1, designed specifically for COVID-19 was utilised. We first considered historical data for Australia before it eliminated COVID-19 (equivalent to an outbreak generating 74 new cases/day) and one flight per day to NZ with no interventions in place. This gave a median time to an outbreak of 0.2 years (95% range of simulation results: 3 days to 1.1 years) or a mean of 110 flights per outbreak. However, the combined use of a pre-flight PCR test of saliva, three subsequent PCR tests (on days 1, 3 and 12 in NZ), and various other interventions (mask use and contact tracing) reduced this risk to one outbreak after a median of 1.5 years (20 days to 8.1 years). A pre-flight test plus 14 days quarantine was an even more effective strategy (4.9 years; 2,594 flights). For a much lower prevalence (representing only two new community cases per week in the whole of Australia), the annual risk of an outbreak with no interventions was 1.2% and had a median time to an outbreak of 56 years. In contrast the risks associated with travellers from Japan and the United States was very much higher and would need quarantine or other restrictions. Collectively, these results suggest that multi-layered interventions can markedly reduce the risk of importing the pandemic virus via air travel into a COVID-19-free nation. For some low-risk source countries, there is the potential to replace 14-day quarantine with alternative interventions. However, all approaches require public and policy deliberation about acceptable risks, and continuous careful management and evaluation.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34031465 PMCID: PMC8144219 DOI: 10.1038/s41598-021-89807-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Input parameters relating to the countries of origin for the travellers arriving in New Zealand (NZ).
| Parameter | Australia (historical base case)* | Scenario analysis: Japan | Scenario analysis: US |
|---|---|---|---|
| Reported average new cases per day in the period 1 April 2020 to 25 February 2021 (WHO data[ | 74 | 1289 | 104,594 (adjusted for under-reporting**) |
| Average new cases per day per million population (for the time period in the above row and using OECD population data[ | 3.0 | 10.2 | 319.7 |
| Estimated point prevalence per million population of SARS-CoV-2 infection on average day (assuming a 16-day long period that comprises the latent and prodromal periods plus the rest of the infectious period, see Table | 48 | 163 | 5115 |
*In the situation in Australia in early 2021 where COVID-19 elimination status had been achieved (albeit introduced cases being in quarantine and isolation in border facilities), these values are those that could be generated by a large outbreak from a border control failure. See Table 5 for scenario analyses using much lower prevalence values that would better equate to small outbreaks following border control failures in Australia. Furthermore, these historical values also partly represent cases detected at the Australian border and then managed to eliminate any risk of transmission in the community.
** Adjusted for the 1.24 times greater excess deaths in the USA relative to deaths attributable to COVID-19 as per the period 8 March 2020 and 9 January 2021[17].
Figure 1Flow diagram of the modelled movements of air travellers from Australia (when experiencing an outbreak) including the key interventions (simplified and not showing details around travellers seeking medical attention when symptomatic in New Zealand, isolation of identified cases and contact tracing).
Scenario analyses covering different source countries, SARS-CoV-2 infection burdens and flight volumes (with the base case for comparison).
| Scenario/country setting | Intervention | Annual risk of outbreak in NZ | Median waiting time until next outbreak occurs (95% range)**** | Mean number of flights to create one outbreak# |
|---|---|---|---|---|
3 h flight time | None | 96.4% | 76 d (3 d–407 d) | 110 |
| 2 PCR in NZ* | 42.8% | 1.2 y (17 d–6.6 y) | 652 | |
| 3 PCR in NZ** | 36.6% | 1.5 y (20 d–8.1 y) | 800 | |
| Quarantine*** | 13.1% | 4.9 y (66 d–26.2 y) | 2593 | |
| Australia to NZ, as per the historical base case above but with | None | 100% | 4 d (1 d–22 d) | 110 |
| 2 PCR in NZ* | 100% | 23 d (1 d–122 d) | 652 | |
| 3 PCR in NZ** | 100% | 28 d (1 d–150 d) | 800 | |
| Quarantine*** | 100% | 90 d (3 d–480 d) | 2593 | |
| Australia to NZ, as per base case but with | None | 28.3% | 2.1 y (28 d–11.1 y) | 1099 |
| 2 PCR in NZ* | 5.4% | 12.4 y (165 d–65.9 y) | 6520 | |
| 3 PCR in NZ** | 4.5% | 15.2 y (203 d–80.9 y) | 8005 | |
| Quarantine*** | 1.4% | 49.2 y (1.8–262 y) | 25,928 | |
| Australia to NZ, as per the base case but with the prevalence in Australia closer to | None | 1.2% | 56 y (2–297 y) | 29,420 |
| 2 PCR in NZ* | 0.2% | 331 y (12–1760 y) | 174,114 | |
| 3 PCR in NZ** | 0.2% | 406 y (15–2161 y) | 213,809 | |
| Quarantine*** | 0.1% | 1,314 y (48–6991 y) | 691,710 | |
| None | 100% | 23 d (1–124 d) | 34 | |
| 2 PCR in NZ* | 83.0% | 143 d (5 d–2.1 y) | 206 | |
| 3 PCR in NZ** | 77.0% | 173 d (6 d–2.5 y) | 249 | |
| Quarantine*** | 34.3% | 1.7 y (22 d–8.8 y) | 870 | |
| None | 100% | 1 d (1–6 d) | 2 | |
| 2 PCR in NZ* | 100% | 5 d (1–27 d) | 7 | |
| 3 PCR in NZ** | 100% | 6 d (1–32 d) | 9 | |
| Quarantine*** | 100% | 20 d (1–109 d) | 29 |
For each intervention strategy, 1 billion stochastic simulations were run for “Australia base case”, “Australia 20 flights/day” and “Australia 1/10 prevalence”; 100 million simulations for all other country settings.
*Pre-flight saliva test; 2 PCR tests in NZ (on days 1 and 3); until second PCR, passengers wear masks in NZ and self-report symptoms (contacts are traced and quarantined).
**Pre-flight saliva test; 3 PCR tests in NZ (on days 1, 3 and 12); until third PCR, passengers wear masks in NZ and self-report symptoms (contacts are traced and quarantined).
***Pre-flight saliva test; quarantine of all passengers in NZ for 7 days.
#The median waiting time until an outbreak occurs only refers to the time until a plane lands which will cause an outbreak in NZ; further days are needed until a passenger infects somebody, until the infection spreads in NZ to many others, and until an outbreak is officially declared. Passengers who are found positive during one of the NZ based PCR tests or traced and detected secondary cases do not trigger the declaration of an outbreak. Here, an outbreak is assumed to be the out-of-control spread of SARS-CoV-2 which will reach many cases if not prevented by major interventions.
##Due to the very low prevalence, no additional simulations were run for this scenario, but the outbreak probabilities per flight were linearly extrapolated from the corresponding base case simulations (based on 1 billion flights each); the reported output was calculated from the obtained probability per flight as detailed in the Supplementary Information.
Control measures used and their estimated efficacy in preventing SARS-CoV-2 transmission.
| Control measure | Value/s used | Comment |
|---|---|---|
| 62.3% sensitivity | For test sensitivity we used a meta-analysis that gave a sensitivity for saliva testing (PCR) at 62.3% (95%CI: 54.5%–69.6%). This was less than for nasopharyngeal aspirate/swab and throat swab (73.3%, 95%CI: 68.1%–78.0%); and for sputum (97.2%, 95%CI: 90.3%–99.7%)[ | |
| 7, 14 and 21 days | We ran the simulations for three different lengths of quarantine, including 14 days as used in NZ, and longer as in some other settings (e.g., 21 days in China). We assumed a high quality quarantine process where there was no cross-infection within the quarantine facility to facility workers or to other travellers in quarantine. But we assumed no additional PCR testing within quarantine. In reality, NZ combines the 14-day quarantine process with PCR testing (nasopharyngeal swab) upon arrival (“day 1”) (travellers from the majority of countries), and days 3 and 12 (all travellers). This process further helps reduce the risk by allowing for infectious individuals to be put into isolation and so reduce the risk of infecting others who are also in quarantine. But these additional benefits from testing are probably outweighed by the limitations in NZ’s processes that have resulted in various failures of the quarantine/isolation facility system that utilises converted hotels[ | |
| The time course of sensitivity values from Kucirka et al. was used | We used the results of a study[ In the absence of relevant data, we had to assume test result independence i.e., a false negative for a test was not correlated with a false negative for a later test. If both results were negative, we assumed no further follow-up. We considered a wide range of different timing options for PCR tests after arrival in NZ (see the “Results”) | |
| 80% of infected contacts are traced and isolated within 48 h | We used performance data for the cluster of cases in Auckland in August 2020 where the official estimate was 80% of contacts contacted within 48 h (as reported by the Prime Minister)[ | |
| The proportion of infected travellers who when they develop any symptoms | 50% (self-reporting occurs on average 1 day after symptom onset) | We assumed that this proportion is somewhat higher than that for the general community (see below) on the assumption that these travellers would be provided information on the flight and on arrival in NZ on the critical importance of seeking medical attention if they develop any symptoms. They would also be told that such medical attention would be provided free of charge. We assumed PCR confirmation of self-reported symptoms and if a positive test, then we assumed case isolation and potentially triggering contact tracing Of note is that routinely in NZ, 39.5% of people with “fever and cough” symptoms seek medical attention, as reported by the NZ Flutracking surveillance system[ |
| 1 day after detection of index cases | Traced contacts are assumed to be effectively quarantined with no further spread of infection | |
| Mandatory | 66% transmission reduction | We used the results of the most recent meta-analysis we could identify which involved 29 studies on infection with SARS-CoV-2, SARS, or MERS[ |
*See Supplementary Information for consideration of uncertainty and probabilistic sensitivity analysis.
Input parameters used for modelling the potential spread of COVID-19 infections with the stochastic version of CovidSIM (v1.1) with New Zealand as a case study.
| Parameter | Value/s used | Further details for parameter inputs into the modelling |
|---|---|---|
| Latency period | 5 days | We used the best estimate from CDC of a mean of 6 days to symptoms (i.e., the latency period plus the prodromal period)[ |
| Prodromal period | 1 day | There is still uncertainty about the length of the prodromal period for COVID-19, so we used an assumed value for influenza (SD = 25%; 0.25 days, Erlang distribution) |
| Symptomatic period | 10 days (split into 2 periods of 5 days each) | The WHO-China Joint Mission report stated that “the median time from onset to clinical recovery for mild cases is approximately 2 weeks and is 3–6 weeks for patients with severe or critical disease”[ |
| Infections that lead to sickness (symptomatic illness) | 60% | We used the best estimate from CDC of 60% symptomatic and 40% asymptomatic[ |
| Risk of in-flight transmission | 0.00214 per hour of flying | This risk was estimated for transmission from an infectious case on a flight in which there was mandated masking (i.e., masks are mandated for all international flights arriving in NZ at the time of writing in March 2020). It is the risk that an index case infects one of the fellow passengers, not the individual risk of each fellow passengers to acquire infection. See the |
| Flight duration | 3 h | For the Australia to NZ flights (e.g., Sydney to Auckland). Times for flights from Japan and the US in scenario analyses are shown in Table |
| Effective reproduction number (Re) in the NZ post-pandemic setting | 2.5 | We used the best estimate from CDC of R0 = 2.5[ |
| Relative contagious-ness in the prodromal period | 100% | We assumed this was high given that the CDC estimate that 50% of transmission occurs prior to symptom onset[ |
| Contagiousness after the prodromal period | 100% and 50% | In the first five days of symptoms, cases were considered to be fully contagious. In the second five-day period, this was assumed to be at 50%. The latter figure is still uncertain, but is broadly consistent with one study on changing viral load[ |
*See Supplementary Information for consideration of uncertainty and probabilistic sensitivity analysis.
Results of the simulations of the baseline risk (no interventions) and for multi-layered packages of interventions to prevent COVID-19 outbreaks in New Zealand (NZ) (assuming a historical level of infection in Australia that was equivalent to a border failure resulting in an outbreak generating 74 new cases/day (as per Table 1) and mandatory mask use on international flights).
| Strategy | Pre-flight saliva test sensitivity | Quarantine of travellers | PCR tests for travellers (day 1 is arrival day)* | Traced contacts after positive PCR test | Prevented infections in NZ while travellers wear masks** | Symptomatic travellers who self-report symptoms *** | Traced contacts after self-reporting of symptoms | Annual risk of outbreak in NZ | Median waiting time until next outbreak occurs (95% range) | Mean number of flights to create one outbreak |
|---|---|---|---|---|---|---|---|---|---|---|
| No PCR tests, no quarantine | – | – | – | – | – | – | – | 96.4% | 0.2 years (y) (3 days [d]–1.1 y) | 110 |
| 62.3% | – | – | – | – | – | – | 88.4% | 0.3 y (4 d–1.7 y) | 170 | |
| PCR tests | 62.3% | – | day 1 | – | – | – | – | 80.3% | 0.4 y (6 d–2.3 y) | 225 |
| 62.3% | – | days 1 + 3 | – | – | – | – | 65.4% | 0.7 y (9 d–3.5 y) | 344 | |
| 62.3% | – | days 1 + 3 | 75% | – | – | – | 65.3% | 0.7 y (9 d–3.5 y) | 345 | |
| 62.3% | – | days 1 + 3 | 75% | – | 50% | 75% | 58.9% | 0.8 y (10 d–4.2 y) | 411 | |
| 62.3% | – | days 1 + 3 | 75% | 66% | – | – | 49.8% | 1 y (13 d–5.4 y) | 530 | |
| 62.3% | – | days 1 + 3 | 75% | 66% | 50% | 75% | 42.8% | 1.2 y (17 d–6.6 y) | 653 | |
| 62.3% | – | days 1 + 3 + 12 | – | – | – | – | 63.9% | 0.7 y (9 d–3.6 y) | 359 | |
| 62.3% | – | days 1 + 3 + 12 | 75% | – | – | – | 63.5% | 0.7 y (9 d–3.7 y) | 362 | |
| 62.3% | – | days 1 + 3 + 12 | 75% | 50% | 75% | 57.2% | 0.8 y (11 d–4.4 y) | 431 | ||
| 62.3% | – | days 1 + 3 + 12 | 75% | 66% | – | – | 43.0% | 1.2 y (16 d–6.6 y) | 650 | |
| 62.3% | – | days 1 + 3 + 12 | 75% | 66% | 50% | 75% | 36.6% | 1.5 y (20 d–8.1 y) | 802 | |
| Quarantine | 62.3% | 7 days | – | – | – | – | – | 67.8% | 0.6 y (8 d–3.3 y) | 322 |
| 62.3% | 14 days | – | – | – | – | – | 13.1% | 4.9 y (66 d–26.2 y) | 2594 | |
| 62.3% | 21 days | – | – | – | – | – | 0.0% | n.a. | 745,000 | |
One billion stochastic simulations were run for each intervention strategy. Result values typically rounded to three meaningful digits. Travellers are allowed to move freely in NZ from arrival to the last PCR test or after being released from quarantine (see Fig. 1).
*A range of days were considered, but the 1 + 3 + 12 day option is the one typically used for travellers to NZ (albeit combined with quarantine for all travellers to NZ).
**Prevention of secondary infections due to wearing of masks by travellers when in NZ up to the time of the last PCR test.
***The given fraction of passengers who report having developed symptoms while staying in NZ to the health system; they are assumed to be isolated one day after symptom onset and contact tracing may occur after this; traced contacts are PCR tested and isolated after another delay of one day.